Anika Therapeutics (ANIK) Gains from Investment Securities (2020 - 2021)
Anika Therapeutics' (ANIK) quarterly Gains from Investment Securities came in at $825000.0 in Q4 2021, up 106.6% year-over-year from $399322.4 in Q4 2020, and up 123.91% quarter-over-quarter from -$3.4 million in Q3 2021.
Powered by 
Analysis
Anika Therapeutics (ANIK) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Anika Therapeutics (ANIK) has reported Gains from Investment Securities for 2 consecutive years, with $825000.0 the latest figure, recorded in Q4 2021.
- On a quarterly basis, Gains from Investment Securities rose 106.6% year-over-year to $825000.0 in Q4 2021; TTM through Sep 2022 was $825000.0, a 102.4% increase from a year earlier, with the FY2021 full-year figure at -$21.1 million, up 26.41% from the prior year.
- Gains from Investment Securities was $825000.0 for Q4 2021 at Anika Therapeutics, up from -$3.4 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $4.2 million in Q2 2020 and troughed at -$24.5 million in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Anika Therapeutics | 277.93 Mn | 239.52 Mn | 21.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 825,000.00 |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | -13.65 Mn |
| Mar 31, 2021 | -4.82 Mn |
| Dec 31, 2020 | -12.50 Mn |
| Sep 30, 2020 | 4.15 Mn |
| Jun 30, 2020 | 4.20 Mn |
| Mar 31, 2020 | -24.52 Mn |